drugset / Trial / NCT04816071

Essential Amino Acid Supplementation in Older Adult COVID-19 Patients

NCT04816071

Phase 2/3 Withdrawn University of Arkansas
RandomizedParallel-groupDouble-blindTreatment

Summary

A 4-week treatment of essential amino acids or placebo to participants with: 1) negative COVID-19 test with exposure, or 2) positive COVID-19 test and no or mild symptoms. The study team will measure change in symptoms. Participants will complete symptom surveys for 4 weeks and once at 8 and 12 weeks as well as pre- and post-assessments.

Timeline

Start
2021-05-01
Primary completion
2021-05-01
Completion
2021-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Essential Aminoacids Unknown 18 g

Indications